ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1010

Proton Pump Inhibitors Suppress IL-1 Mediated Carditis in a Murine Model of Kawasaki Disease

Paul Tsoukas1, Melissa Kleinau2, Lysa Langevin2, Lily Morikawa3, Trang Duong1, Suzanne Tam4 and Rae Yeung5, 1Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, ON, 4Hospital for Sick Children, Toronto, ON, 5The Hospital for Sick Children, Toronto, ON, Canada

Meeting: ACR Convergence 2021

Keywords: Inflammasome, Mouse, Pediatric rheumatology, Therapy, alternative, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Pediatric Rheumatology – Basic Science Poster (1007–1013)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Kawasaki disease (KD), is the leading cause of acquired heart disease in childhood. Up to 20% of patients may develop coronary artery lesions (CAL) despite standard of care treatment with intravenous immunoglobulin (IVIg).

Murine and patient data indicate Interleukin-1 (IL-1) contributes to CALs. Proton pump inhibitors (PPI), a class of medications used to limit gastric acid secretion, have also been shown to have anti-inflammatory properties: 1) decreasing macrophage IL-1β secretion in vitro and 2) improving clinical outcomes in IL-1 mediated murine models.

This study aims to determine if PPIs inhibit IL-1β production and resulting CAL in the Lactobacillus casei cell wall extract (LCWE) induced coronary arteritis murine model of KD.

Methods: Bone marrow derived macrophages (BMDMs) were obtained from adult mice and stimulated with Pam3Cys and Lactobacillus casei cell wall extract (LCWE), in the presence or absence of PPIs. To exclude toxic effects, viability was tested via flow cytometry and trypan blue exclusion. Electrolyte flux was measured via fluorescent imaging plate reader. In vivo, KD was induced by intraperitoneal LCWE injection. Mice were injected with LCWE alone, LCWE+PPI, saline or PPI alone. Coronary artery inflammation was scored by a blinded pathologist. Using ELISA, serum IL-1β and NT-proBNP were measured.

Results: Following stimulation with either Pam3Cys or LCWE, PPIs inhibited BMDM IL-1β production in a dose-dependent and drug class independent manner. Inflammasome activation was prevented by PPI inhibition of signal two. In vivo, compared to untreated KD diseased mice, those treated with PPI were shown to have significantly reduced coronary artery inflammation.

Conclusion: IL-1 is essential for the development of LCWE induced murine KD and anti-IL-1 therapy have been shown to prevent myocardial inflammatory changes. Our data indicate that PPIs have extra-gastrointestinal anti-inflammatory properties in a murine KD model preventing IL-1 induced coronary artery inflammation. PPIs may be a novel inexpensive, oral, and safe adjuvant anti-IL-1 medication to treat KD.


Disclosures: P. Tsoukas, None; M. Kleinau, None; L. Langevin, None; L. Morikawa, None; T. Duong, None; S. Tam, None; R. Yeung, None.

To cite this abstract in AMA style:

Tsoukas P, Kleinau M, Langevin L, Morikawa L, Duong T, Tam S, Yeung R. Proton Pump Inhibitors Suppress IL-1 Mediated Carditis in a Murine Model of Kawasaki Disease [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/proton-pump-inhibitors-suppress-il-1-mediated-carditis-in-a-murine-model-of-kawasaki-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/proton-pump-inhibitors-suppress-il-1-mediated-carditis-in-a-murine-model-of-kawasaki-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology